PTC Therapeutics’s $200 Million Acquisition of Agilis Biotherapeutics

Ambrogio Visconti

Cooley advised Agilis Biotherapeutics on its agreement to be acquired by PTC Therapeutics for $200 million. PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here